Erudio Healtherudio.com
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC trials: what clinicians said in public
No HCP commentary report on a trial sponsored by European Organisation for Research and Treatment of Cancer - EORTC yet. Erudio has found public clinician commentary on 14 clinical trials sponsored by European Organisation for Research and Treatment of Cancer - EORTC, including AMAROS, MINDACT, STRASS2 and SURTIME. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (European Organisation for Research and Treatment of Cancer - EORTC). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| SURTIME NCT01099423 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | synchronous metastatic clear cell renal cell carcinoma | Phase 3 | Deep | View | |||
| MINDACT NCT00433589 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | breast cancer with 0 to 3 positive nodes | Phase 3 | Deep | View | |||
| STRASS2 NCT04031677 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | high-risk retroperitoneal sarcoma | Phase 3 | Deep | View | |||
| AMAROS NCT00014612 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | breast cancer with a positive sentinel node | Phase 3 | Deep | View | |||
| OligoRARE NCT04498767 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | rare oligometastatic cancers | Not applicable | Deep | View | |||
| CATNON NCT00626990 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | 1p/19q non-co-deleted anaplastic glioma | Phase 3 | Deep | View | |||
| STRASS NCT01344018 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | untreated nonmetastatic retroperitoneal sarcoma | Not applicable | Deep | View | |||
| AML-17 NCT00052299 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | previously untreated acute myeloid leukemia in older patients | Phase 3 | Deep | View | |||
| PEACE III NCT02194842 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | metastatic castration-resistant prostate cancer with bone metastases | Phase 3 | Deep | View | |||
| PRIMALung NCT04790253 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | small-cell lung cancer | Not applicable | Deep | View | |||
| TREAT ctDNA NCT05512364 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | ER+/HER2- breast cancer with ctDNA relapse | Phase 3 | Deep | View | |||
| EBIN NCT03235245 · European Organisation for Research and Treatment of Cancer - EORTC StandardView → | unresectable or metastatic melanoma with BRAF V600 mutation | Phase 2 | Standard | View | |||
| NIVOTHYM NCT03134118 · European Organisation for Research and Treatment of Cancer - EORTC StandardView → | previously treated type B3 thymoma and thymic carcinoma | Phase 2 | Standard | View | |||
| APPLE NCT02856893 · European Organisation for Research and Treatment of Cancer - EORTC FocusedView → | advanced EGFR-mutant non-small-cell lung cancer | Phase 2 | Focused | View | |||